Cryoport, Inc. (NASDAQ:CYRX – Free Report) – Investment analysts at Roth Capital dropped their Q1 2025 earnings per share (EPS) estimates for shares of Cryoport in a report released on Wednesday, March 5th. Roth Capital analyst R. Baldry now anticipates that the company will post earnings per share of ($0.34) for the quarter, down from their previous estimate of ($0.32). The consensus estimate for Cryoport’s current full-year earnings is ($0.99) per share. Roth Capital also issued estimates for Cryoport’s Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.30) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.31) EPS and Q4 2026 earnings at ($0.29) EPS.
A number of other research firms have also recently commented on CYRX. Guggenheim began coverage on Cryoport in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 target price on the stock. Roth Mkm decreased their price target on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price target on shares of Cryoport in a research note on Wednesday. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Cryoport presently has an average rating of “Moderate Buy” and an average price target of $12.29.
Cryoport Price Performance
NASDAQ:CYRX opened at $6.23 on Friday. Cryoport has a 52 week low of $4.58 and a 52 week high of $20.10. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $307.96 million, a PE ratio of -1.84 and a beta of 1.59. The stock’s 50-day moving average price is $7.28 and its 200-day moving average price is $7.61.
Cryoport (NASDAQ:CYRX – Get Free Report) last posted its earnings results on Tuesday, March 4th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09). Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The business had revenue of $59.53 million for the quarter, compared to analyst estimates of $58.71 million. During the same quarter last year, the business earned ($0.29) earnings per share.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. lifted its stake in Cryoport by 148.7% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock worth $28,000 after purchasing an additional 2,120 shares in the last quarter. Lazard Asset Management LLC purchased a new position in Cryoport in the 4th quarter worth approximately $51,000. Avanza Fonder AB purchased a new position in Cryoport in the 4th quarter worth approximately $64,000. Quarry LP purchased a new position in Cryoport in the 4th quarter worth approximately $69,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Cryoport in the 3rd quarter worth approximately $82,000. 92.90% of the stock is owned by hedge funds and other institutional investors.
Cryoport Company Profile
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
Further Reading
- Five stocks we like better than Cryoport
- Best Aerospace Stocks Investing
- Is Myers Industries Poised for a Breakout?
- Expert Stock Trading Psychology Tips
- Is BigBear.ai’s 25% Plunge a False Alarm or Fire Sale?
- When to Sell a Stock for Profit or Loss
- Broadcom Confirmed Its AI Outlook: Stock to Hit New Highs Soon
Receive News & Ratings for Cryoport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with MarketBeat.com's FREE daily email newsletter.